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Appendix 
 
International Carotid Stenting Study investigators 
 
Steering Committee:  
A Algra, J Bamford (chair), J Beard, M Bland, A W Bradbury, M M Brown (chief investigator), A 
Clifton, P Gaines, W Hacke, A Halliday, I Malik, J L Mas, A J McGuire, P Sidhu, G Venables.  
 
Credential committee:  
A Bradbury, M M Brown, A Clifton, P Gaines.  
 
Data Monitoring Committee:  
R Collins, A Molyneux, R Naylor, C Warlow (chair).  
 
Outcome Event Adjudication Committee:  
J M Ferro, D Thomas.  
 
Central office staff at UCL Institute of Neurology:  
L H Bonati, L Coward, J Dobson (trial statistician), D. Doig, J Ederle, R F Featherstone (trial 
manager), F. Kennedy, H Tindall, E Turner, D J H McCabe, A Wallis.  
 
Participating countries and centres (number of enrolled patients per centre; local investigators): 
Australia: Austin Health, Heidelberg (46; M Brooks, B Chambers [principal investigator], A Chan, P 
Chu, D Clark, H Dewey, G Donnan, G Fell, M Hoare, M Molan, A Roberts, N Roberts). Box Hill 
Hospital (Monash University), Melbourne (25; B Beiles, C Bladin [principal investigator], C Clifford, 
G Fell, M Grigg, G New). Monash Medical Centre, Clayton (26; R Bell, S Bower, W Chong, M Holt, 
A Saunder, P G Than [principal investigator]). Princess Alexandra Hospital, Brisbane (48; S Gett, D 
Leggett, T McGahan [principal investigator], J Quinn, M Ray, A Wong, P Woodruff ). Repatriation 
General Hospital, Daw Park, Adelaide (6; R Foreman, D Schultz [principal investigator], R Scroop, B 
Stanley). Royal Melbourne Hospital, Melbourne (57; B Allard, N Atkinson, W Cambell, S Davis 
[principal investigator], P Field, P Milne, P Mitchell, B Tress, B Yan). Royal Hobart Hospital, Hobart 
(18; A Beasley, D Dunbabin, D Stary, S Walker [principal investigator]). 
Belgium: Antwerp University Hospital, Antwerp (10; P Cras, O d’Archambeau, J M H Hendriks 
[principal investigator], P Van Schil). A Z St Blasius, Dendermonde (5; M Bosiers [principal 
investigator], K Deloose, E van Buggenhout). A Z Sint Jan Brugge-Oostende, Campus Brugge, 
Brugges (18; J De Letter, V Devos, J Ghekiere, G Vanhooren [principal investigator]). Cliniques 
Universitaires St Luc, Bruxelles (1; P Astarci, F Hammer, V Lacroix, A Peeters [principal 
investigator], R Verhelst). Imelda Ziekenhuis, Bonheiden (3; L DeJaegher [principal investigator], A 
Peeters, J Verbist). 
Canada: CHUM Notre-Dame Hospital, Montreal (30; J-F Blair, J L Caron, N Daneault, M-F Giroux, F 
Guilbert, S Lanthier, L-H Lebrun, V Oliva, J Raymond, D Roy [principal investigator], G Soulez, A 
Weill). Foothills Medical Center, Calgary (4; M Hill [principal investigator], W Hu, M Hudion, W 
Morrish, G Sutherland, J Wong).  
Finland: Helsinki University Central Hospital, Helsinki (33; A Albäck, S Curtze, H Harno, P Ijäs, M 
Kaste (principal investigator) , K Lappalainen, M Lepäntalo, A Meretoja, S Mustanoja, T Paananen, M 
Porras, J Putaala, M Railo, T Sairanen, L Soinne, A Vehmas, P Vikatmaa).  
Germany: Otto von Guericke University, Magdeburg (9; M Goertler [principal investigator], Z Halloul, 
M Skalej). 
Ireland: Beaumont Hospital, Dublin (4; P Brennan, C Kelly, A Leahy, J Moroney [principal 
investigator], J Thornton).  
Netherlands: Academic Medical Center, Amsterdam (56; M J W Koelemay, P J Nederkoorn [principal 
investigator], J A A Reekers, Y B W E M Roos). Erasmus Medical Center, Rotterdam (75; J M 
Hendriks, P J Koudstaal [principal investigator], P M T Pattynama, A van der Lugt, L C van Dijk, M R 
H M van Sambeek, H van Urk, H J M Verhagen). Haga Teaching Hospitals, The Hague (45; C M A 
Bruijninckx, S F de Bruijn, R Keunen, B Knippenberg, A Mosch [principal investigator], F Treurniet, 
L van Dijk, H van Overhagen, J Wever). Isala Klinieken, Zwolle (14; F C de Beer,J S P van den Berg 
[principal investigator], B A A M van Hasselt, D J Zeilstra). Medical Center Haaglanden, The Hague 
(3; J Boiten [principal investigator], J C A de Mol van Otterloo, A C de Vries, G J Lycklama a 
Nijeholt, B F W van der Kallen). UMC St Radboud, Nijmegen (13; J D Blankensteijn, F E De Leeuw, 
L J Schultze Kool [principal investigator], J A van der Vliet). University Medical Center, Utrecht (270; 
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G J de Borst, G A P de Kort, L J Kapelle [principal investigator], T H Lo, W P Th M Mali, F Moll, HB 
van der Worp, H Verhagen).  
New Zealand: Auckland City Hospital, Auckland (40; P A Barber, R Bourchier, A Hill, A Holden, J 
Stewart [principal investigator]). 
Norway: Rikshospitalet University Hospital, Oslo (16; S J Bakke [principal investigator], K Krohg-
Sørensen, M Skjelland, B Tennøe).  
Poland: Institute of Psychiatry and Neurology (2nd Department of Neurology & Department of 
Neuroradiology) and Medical University of Warsaw (2nd Department of General, Vascular and 
Oncological Surgery), Warsaw (20; P Bialek, Z Biejat, W Czepiel, A Czlonkowska [principal 
investigator], A Dowzenko, J Buczek, A Kobayashi, M Lelek, J Polanski).  
Slovenia: University Medical Center, Ljubljana (12; J Kirbis, Z Milosevic, B Zvan [principal 
investigator]).  
Spain: Hospital Clinic, Barcelona (18; J Blasco, A Chamorro [principal investigator], J Macho, V 
Obach, V Riambau, L San Roman). Parc Taulí Sabadell Hospital, Barcelona (33; J Branera, D Canovas 
[principal investigator], Jordi Estela, A Gimenez Gaibar, J Perendreu).  
Sweden: Skåne University Hospital, Malmö (67; K Björses, A Gottsäter [principal investigator], K 
Ivancev, T Mätzsch, B Sonesson)). Sodersjukhuset, Stockholm (55; B Berg, M Delle, J Formgren, P 
Gillgren, T-B Kaell, P Konrad [principal investigator], N Nyman, R Takolander). The Karolinska 
Institute, Stockholm (5; T Andersson, J Malmstedt, M Soderman, C Wahlgren, N Wahlgren [principal 
investigator]).  
Switzerland: Centre Hospitalier Universitaire Vaudois, Lausanne (12; S Binaghi, L Hirt, P Michel 
[principal investigator], P Ruchat). University Hospital Basel, Basel (94; L H Bonati, S T Engelter, F 
Fluri, L Guerke, A L Jacob, E Kirsch, P A Lyrer [principal investigator], E-W Radue, P Stierli, M 
Wasner, S Wetzel). University Hospital of Geneva, Geneva (16; C Bonvin, A Kalangos, K Lovblad, N 
Murith, D Ruefenacht, R Sztajzel [principal investigator]).  
United Kingdom: Addenbrookes Hospital, Cambridge (5; N Higgins, P J Kirkpatrick, P Martin 
[principal investigator]). K Varty Birmingham Heartlands Hospital, Birmingham (11; D Adam, J Bell, 
A W Bradbury, P Crowe, M Gannon, M J Henderson, D Sandler, R A Shinton [principal investigator], 
J M Scriven, T Wilmink). Lancashire Teaching Hospitals NHS Trust, Preston (2; S D’Souza, A Egun, 
R Guta, S Punekar, D M Seriki [principal investigator], G Thomson). Liverpool Royal Infirmary (21) 
and the Walton Centre, Liverpool (7; J A Brennan, T P Enevoldson, G Gilling-Smith [principal 
investigator], D A Gould, P L Harris,R G McWilliams, H-C Nahser, R White). Manchester Royal 
Infirmary, Manchester (2; K G Prakash, F Serracino-Inglott, G Subramanian [principal investigator], J 
V Symth, M G Walker). Newcastle Acute Hospitals NHS Foundation Trust, Newcastle upon Tyne 
(108; M Clarke, M Davis, S A Dixit, P Dorman [principal investigator], A Dyker, G Ford, A Golkar, R 
Jackson, V Jayakrishnan, D Lambert, T Lees, S Louw, S Macdonald, A D Mendelow, H Rodgers, J 
Rose, G Stansby, M Wyatt). North Bristol NHS Trust, Frenchay Hospital, Bristol (13; T Baker, N 
Baldwin [principal investigator], L Jones, D Mitchell, E Munro, M Thornton). Royal Free Hospital, 
London (1; D Baker, N Davis, G Hamilton [principal investigator], D McCabe, A Platts, J Tibballs). 
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (151; J Beard, T Cleveland, D Dodd, P 
Gaines, R Lonsdale, R Nair, A Nassef, S Nawaz, G Venables [principal investigator]). St George’s 
University of London and St George’s NHS Healthcare Trust, London (58; A Belli, A Clifton, G 
Cloud, A Halliday, H Markus [principal investigator], R McFarland, R Morgan, A Pereira, A 
Thompson). St Mary’s Hospital, Imperial College Healthcare NHS Trust, London (13; J Chataway 
[principal investigator], N Cheshire, R Gibbs, M Hammady, M Jenkins, I Malik, J Wolfe). University 
College London Hospitals NHS FoundationTrust, London (51; M Adiseshiah, C Bishop, S Brew, J 
Brookes, M M Brown [principal investigator], R Jäger, N Kitchen). University Hospital of South 
Manchester, Wythenshawe, Manchester (58; R Ashleigh, S Butterfield, G E Gamble, C McCollum 
[principal investigator], A Nasim, P O’Neill, J Wong). Western Infirmary, Glasgow (5; R D Edwards, 
K R Lees, A J MacKay, J Moss [principal investigator], P Rogers).  
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Supplementary figure 1: Duration of follow-up from randomisation by treatment group 
 
 
 
In total there are 7354·4 patient years of follow-up (until time of last follow-up or death). CAS, carotid 
stenting: n=853, median follow-up = 4·2 years, interquartile range (IQR) 3·0-5·4 (max = 10·0 years, 
153 deaths). CEA, carotid endarterectomy, n=857, median FU = 4·2 years, IQR 3·0-5·2 (max = 9·6 
years, 129 deaths). 
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Supplementary table 1: technical information for stenting procedures 
 
 Total (n=828*) 
Cerebral protection device used  
Yes 585 (71%) 
No 239 (29%) 
Unknown 4 (0.5%) 
Stent type used  
Closed stent design 371 (45%) 
Open stent design 367 (44%) 
No stent deployed 64 (8%) 
Stent deployment or type unknown 26 (3%) 
Peri-procedural antiplatelet therapy  
Any double antiplatelet therapy 674 (81%) 
Aspirin and clopidogrel 594 
Aspirin, dipyridamole and clopidogrel  58 
Aspirin and dipyridamole 12 
Aspirin and ticlopidin 6 
Clopidogrel and dipyridamole 4 
Single antiplatelet therapy 71 (9%) 
Aspirin only 29 
Clopidogrel only 42 
No antiplatelet therapy 16 (2%) 
Missing peri-procedural medication data 67 (8%) 
*Number of patients randomly allocated stenting in whom the procedure was initiated 
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Supplementary table 2: technical information for endarterectomy procedures 
 
 Total (n=821*) 
Type of anaesthesia  
General anaesthesia 650 (79%) 
Local anaesthesia 144 (18%) 
Unknown 27 (3%) 
Shunt used  
Yes 324 (39%) 
No 494 (60%) 
Unknown 3 (0.4%) 
Type of reconstruction  
Standard with patch 459 (56%) 
Standard without patch 182 (22%) 
Eversion 49 (6%) 
Vein interposition 3 (0.4%) 
Unknown 128 (16%) 
 
*Number of patients randomly allocated endarterectomy in whom the procedure was initiated 
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Supplementary table 3: Drug treatment and blood pressure levels during follow-up (intention-to-
treat population) 
 
 
1 year 5 years 
 
Stenting Endarterectomy Stenting Endarterectomy 
Drug treatment (n patients with data) 714 751 343 329 
Any antiplatelet 668 (94%) 688 (92%) 303 (88%) 284 (86%) 
Aspirin alone 401 (56%) 413 (55%) 197 (57%) 169 (51%) 
Clopidogrel alone 79 (11%) 79 (11%) 40 (12%) 46 (14%) 
Dipyridamole + aspirin or clopidogrel 130 (18%) 154 (21%) 48 (14%) 48 (15%) 
Aspirin + clopidogrel 55 (8%) 34 (5%) 14 (4%) 17 (5%) 
Anticoagulation (Vitamin K antagonists) 36 (5%)* 57 (8%)* 23 (7%) 33 (10%) 
Other anticoagulation or antiplatelet 3 (0%) 10 (1%) 5 (1%) 4 (1%) 
Any anticoagulation or antiplatelet 696 (97%) 731 (97%) 322 (94%) 313 (95%) 
Antihypertensive 510 (71%) 566 (75%) 286 (83%)* 250 (76%)* 
Lipid lowering 584 (82%) 629 (84%) 299 (87%) 282 (86%) 
Blood pressure (n patients with data) 664† 685† 313† 302† 
Mean systolic mmHg 147 (22)* 144 (22)* 142 (22) 143 (23) 
Mean diastolic mmHg 79 (12)* 78 (11)* 77 (12) 76 (12) 
 
Data are number (percent) or mean (standard deviation) of patients with available information. *P-
value <0.05 (statistical comparison between stenting and endarterectomy using Chi-square test for 
specified drug treatments and t-test for blood pressures). †Numbers of patients with data are 663 and 
684 (1 year), and 312 and 301 (5 year), for diastolic blood pressure.  
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Supplementary table 4: Number of main outcome events between randomisation and end of 
follow-up (intention-to-treat population) 
 
  Procedural period* Follow-up period 
(excluding procedural 
period)** 
Full study period 
(including procedural 
period 
 CAS 
(n=837) 
CEA 
(n=836) 
CAS 
(n=853) 
CEA 
(n=857) 
CAS 
(n=853) 
CEA 
(n=857) 
Any stroke 59 27 65 47 119 72 
Stroke territory       
Ipsilateral carotid stroke 51 24 35 31 84 53 
Contralateral carotid or 
vertebrobasilar stroke 
7 4 32 17 39 21 
Contralateral 6 2 25 9 31 11 
Vertebrobasilar 2 2 8 8 10 10 
Unknown territory 2 0 3 4 5 4 
Stroke type       
Ischemic 57 21 53 38 107 57 
Haemorrhagic 2 5 10 7 12 12 
Uncertain type 0 1 4 5 4 6 
Stroke severity       
Non-disabling 36 12 40 16 73 27 
Disabling 15 13 16 26 31 39 
Fatal 8 3 14 8 22 11 
All cause death 11† 4 142† 125 153 129 
Non-stroke death 4 1 127 117 131 118 
Myocardial infarction‡ 3 5 - - - - 
Non-fatal 0 5 - - - - 
Fatal 3 0 - - - - 
Cranial nerve palsy‡ 1 45 - - - - 
Disabling cranial nerve palsy 1 1 - - - - 
Access site haematoma‡ 30 50 - - - - 
Severe haematoma 8 28 - - - - 
 
CAS, carotid stenting. CEA, carotid endarterectomy. Data are number of first outcome events of each 
type within each timing category. A patient may therefore contribute more than one type of outcome 
event within a timing category and more than one outcome event of the same type across timing 
categories. 53 patients (31 CAS, 22 CEA) had more than one outcome event during follow-up. *Events 
occurring within 30 days of first revascularisation treatment (irrespective of whether this was the 
randomly allocated treatment or not). **Also includes events occurring between randomisation and 
treatment (2 CAS, 1 CEA) and events among patients not receiving revascularisation treatment (7 
CAS, 15 CEA events, in 4 CAS, 11 CEA patients). †The death of 1 patient with fatal procedural stroke 
(i.e. a stroke occurring within 30 days of treatment and leading to death within 30 days of stroke onset) 
was counted in all-cause death in the follow-up period rather than the procedural period, as the patient 
died more than 30 days after treatment. ‡ Outcome events only adjudicated in procedural period. 
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Supplementary figure 2: Hazard ratios of fatal or disabling stroke between randomisation and 
end of follow-up in patient subgroups.  
 
 
CAS, carotid stenting. CEA, carotid endarterectomy. Subgroups are defined according to baseline 
characteristics and analyzed by intention to treat for all available follow-up, apart from time from event 
to procedure, which is analyzed per protocol. Interaction P-values are calculated using likelihood ratio 
tests in the Cox regression models. *Data are number of events of first fatal or disabling stroke / 
number of patients, and Kaplan-Meier estimate of cumulative risk at 5 years. Patients with missing 
information were excluded from the analysis. **Time from most recent ipsilateral event before 
randomisation to the date of treatment, analysed per protocol from the time of procedure. All subgroups 
for analysis were pre-specified except for treated hyperlipidaemia which was added post-hoc. 
Age
<70 yrs
>=70 yrs
Sex
Male
Female
Treated hypertension
No
Yes
Treated hyperlipidaemia
No
Yes
Diabetes
No
Yes
Ipsilateral stenosis
50-69%
70-99%
Contralateral stenosis
0-49%
50-69%
70-99%
Occluded
Type of most recent event
Stroke
TIA
AFX
Centre experience
Experienced
Supervised
Centre recruitment
<50 pts
>=50 pts
Time from event to procedure**
<=14 days
>14 days
Subgroups
20/395
32/458
33/601
19/252
16/256
34/587
21/321
29/522
36/669
16/184
4/92
48/761
31/565
10/128
7/105
2/49
32/419
17/273
2/148
44/751
8/102
28/302
24/551
15/205
34/623
Ev/Pts
CAS
4.9
7.7
5.6
8.2
6.0
6.4
6.7
5.9
5.6
9.4
3.9
6.7
5.7
9.2
6.2
4.1
8.7
5.6
1.6
6.1
8.8
10.9
4.0
7.7
5.7
%*
16/404
33/453
29/606
20/251
12/255
37/596
17/288
32/563
40/669
9/188
7/76
42/781
33/561
6/142
7/110
2/37
22/399
21/303
5/142
38/760
11/97
19/307
30/550
7/151
36/668
Ev/Pts
CEA
4.5
8.4
5.3
9.4
5.1
7.2
6.8
6.5
6.8
5.2
9.6
6.2
7.1
3.7
7.0
6.2
6.5
7.6
3.6
5.9
12.1
7.1
6.2
6.6
6.2
%*
1.26 (0.65, 2.43)
0.96 (0.59, 1.56)
1.15 (0.70, 1.90)
0.92 (0.49, 1.73)
1.39 (0.65, 2.95)
0.90 (0.57, 1.44)
1.07 (0.57, 2.04)
0.98 (0.59, 1.62)
0.91 (0.58, 1.42)
1.72 (0.76, 3.91)
0.47 (0.14, 1.59)
1.17 (0.77, 1.77)
0.92 (0.56, 1.50)
2.09 (0.75, 5.80)
0.96 (0.33, 2.78)
0.73 (0.10, 5.18)
1.37 (0.80, 2.36)
0.96 (0.50, 1.82)
0.34 (0.07, 1.76)
1.17 (0.76, 1.81)
0.65 (0.26, 1.65)
1.53 (0.86, 2.74)
0.78 (0.46, 1.34)
1.56 (0.63, 3.82)
1.00 (0.63, 1.60)
Ratio (95% CI)
Hazard
0.520
0.584
0.340
0.821
0.175
0.155
0.835
0.217
0.260
0.095
0.390
p-value
Interaction
Favours CAS  Favours CEA 
1.3 .5 .75 1.5 2 3 4 5 7
       Hazard ratio
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Supplementary figure 3: Hazard ratios of procedural stroke, procedural death or 
ipsilateral stroke occurring during follow-up in different patient subgroups. 
CAS, carotid stenting. CEA, carotid endarterectomy. Subgroups are defined according to baseline 
characteristics and analysed by intention to treat for all available follow-up, apart from time from event 
to procedure, which is analysed per protocol. Interaction P-values are calculated using likelihood ratio 
tests in the Cox regression models. *Data are number of events of first procedural stroke or procedural 
death or ipsilateral stroke during follow-up / number of patients, and Kaplan-Meier estimate of 
cumulative risk at 5 years. Patients with missing information were excluded from the analysis. **Time 
from most recent ipsilateral event before randomisation to the date of treatment, analysed per protocol 
from the time of procedure. 
  
Age
<70 yrs
>=70 yrs
Sex
Male
Female
Treated hypertension
No
Yes
Treated hyperlipidaemia
No
Yes
Diabetes
No
Yes
Ipsilateral stenosis
50-69%
70-99%
Contralateral stenosis
0-49%
50-69%
70-99%
Occluded
Type of most recent event
Stroke
TIA
AFX
Centre experience
Experienced
Supervised
Centre recruitment
<50 pts
>=50 pts
Time from event to procedure**
<=14 days
>14 days
Subgroups
35/395
60/458
65/601
30/252
28/256
65/587
35/321
58/522
65/669
30/184
5/92
90/761
62/565
17/128
12/105
2/49
59/419
28/273
7/148
83/751
12/102
46/302
49/551
22/205
67/623
Ev/Pts
CAS
9.1
14.2
11.3
13.0
11.3
12.0
11.7
11.7
10.1
18.3
6.0
12.5
11.9
14.0
11.1
4.1
15.1
10.3
5.7
11.5
14.8
16.8
9.2
12.0
11.6
%*
22/404
35/453
32/606
25/251
12/255
45/596
17/288
40/563
44/669
13/188
6/76
51/781
35/561
9/142
10/110
2/37
29/399
22/303
5/142
50/760
7/97
18/307
39/550
5/151
44/668
Ev/Pts
CEA
6.0
8.3
5.9
10.4
4.9
8.3
6.7
7.6
7.1
7.7
8.8
7.1
6.8
6.5
10.1
6.2
8.0
7.7
3.7
7.2
7.5
6.3
7.8
3.8
7.1
%*
1.65 (0.97, 2.81)
1.77 (1.17, 2.69)
2.12 (1.39, 3.23)
1.22 (0.72, 2.07)
2.43 (1.24, 4.78)
1.50 (1.02, 2.19)
1.89 (1.06, 3.38)
1.61 (1.07, 2.40)
1.52 (1.04, 2.23)
2.44 (1.27, 4.67)
0.70 (0.21, 2.28)
1.87 (1.33, 2.63)
1.80 (1.19, 2.72)
2.22 (0.99, 4.97)
1.32 (0.57, 3.04)
0.74 (0.10, 5.23)
2.01 (1.29, 3.13)
1.48 (0.84, 2.58)
1.32 (0.42, 4.15)
1.73 (1.22, 2.45)
1.69 (0.66, 4.29)
2.77 (1.60, 4.77)
1.27 (0.83, 1.93)
3.32 (1.26, 8.77)
1.66 (1.14, 2.43)
Ratio (95% CI)
Hazard
0.836
0.110
0.213
0.646
0.214
0.118
0.371
0.618
0.964
0.024
0.172
p-value
Interaction
Favours CAS  Favours CEA 
1.3 .5 .75 1.5 2 3 4 5 7
       Hazard ratio
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Supplementary figure 4: Functional ability measured by the modified Rankin Scale during 
follow-up 
 
 
CAS, carotid stenting. CEA, carotid endarterectomy. Permutation test* comparing Rankin scores 
between the two groups at 1 year, unadjusted: p=0·70, adjusted for baseline mRS: p=0·11; at 5 years, 
unadjusted: p=0·54, adjusted for baseline mRS: p=0·98. *According to Howard et al., Stroke 
2012;43(3):664-669.  
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Supplementary figure 5: Meta-analysis of death or any stroke occurring between randomisation 
and 30 days after treatment or ipsilateral stroke during follow-up 
 
Update of the Cochrane Collaborative Group Intervention Review of randomised trials comparing 
endovascular treatment with endarterectomy for symptomatic carotid stenosis.1 Only trials using 
primary carotid stenting in their endovascular treatment group, i.e. with routine placement of a stent, 
and only trials reporting outcomes in symptomatic patients were included. The combined outcome 
event of any stroke or death occurring between randomisation and 30 days after treatment (or 30 days 
after randomisation in patients receiving neither CAS nor CEA), or ipsilateral stroke occurring during 
follow-up is compared. Data are numbers of patients with events, total numbers of patients and Mantel-
Haenszel random-effects odds ratios including 95% confidence intervals (CI) with endarterectomy as 
the reference treatment. Squares represent point estimates of odds ratios at trial level, with 95% CI as 
horizontal bars. The diamond at the bottom represents the summary OR and 95% CI. We quantified 
heterogeneity using the I² statistic.2  Review Manager software, version 5.2.6 was used. Data from the 
following trials are included: Kentucky,3 SPACE,4 EVA-3S,5 Regensburg,6 BACASS,7 ICSS,8 
CREST9. Studies are listed by the year of the initial publication of results. CAS, carotid artery stenting; 
CEA, carotid endarterectomy. 
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